Blood saving program: a multicenter Italian experience.
To assess the causes of failure in a blood saving program and the consequent need for homologous transfusions during major orthopedic surgery, data were collected from six orthopedic centers where an autotransfusion program was carried out from 1992-1994. The 1,576 (1,016 female and 560 male) patients studied (average age 63.6 +/- 10 years) were treated either for total hip prosthesis (1,144 pts) total knee prosthesis (212 pts), plate and screw removal plus hip prosthesis (8 pts), hip revision (cup 48 pts, stem 10 pts, cup plus stem 146 pts) and total knee revision (8 pts). Ninety percent of patients did not undergo homologous transfusions, which was significantly connected to: male sex (8% versus 11.7% p = 0.02), younger age (63.2 vs 66.9 years, p = 0.0001), higher weight (male 76 vs 70.7 Kg. p = 0.003, female 65.6 vs 61.9 Kg. p = 0.0003); higher baseline Hb (13.9 vs 12.8 g/dl, p = 0.0041), shorter operation time (110 vs 128 minutes, p = 0.0001); use of indobufen for antithromboembolic prophylaxis (indobufen 4.6% vs heparin calcium 15.2% vs low molecular weight heparin 9% p = 0.0001). On the contrary, the factors favoring homologous transfusions were: peripheral anesthesia (spinal and epidural 15.3% vs general 9.3% vs integrated 9.8% p = 0.016), total hip or knee revision, fixation device removal before hip prosthesis, systemic hypertension and coronary heart disease.
D000368:Aged; D000704:Analysis of Variance; D016063:Blood Loss, Surgical; D001804:Blood Transfusion, Autologous / Q000706:statistics & numerical data*; D005260:Female; D005340:Fibrinogen / Q000032:analysis / Q000378:metabolism; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism; D006622:Hip Prosthesis / Q000009:adverse effects* / Q000592:standards; D006801:Humans; D007558:Italy; D007720:Knee Prosthesis / Q000009:adverse effects* / Q000592:standards; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D010976:Platelet Count; D011183:Postoperative Complications / Q000517:prevention & control; D012737:Sex Factors; D013923:Thromboembolism / Q000517:prevention & control
D006454:Hemoglobins; D010975:Platelet Aggregation Inhibitors; D005340:Fibrinogen